Literature DB >> 28947988

Association analysis of APO gene polymorphisms with ischemic stroke risk: a case-control study in a Chinese Han population.

Rongjun Xiao1, Shuaiqi Sun1, Jiayi Zhang2, Yongri Ouyang2, Ning Zhang2, Min Yang2, Tianbo Jin2, Ying Xia1.   

Abstract

This study aimed to assess the association of APO gene polymorphisms and ischemic stroke risk in a Chinese Han population. In this case-control study, we genotyped 14 single nucleotide polymorphisms (SNPs) in 3 APO genes in 488 cases and 503 controls using Sequenom Mass-ARRAY technology and evaluated their association with ischemic stroke using the χ2 and genetic model analysis. In the allelic model analysis, we determined three SNPs were significantly associated with ischemic stroke: rs693 with a p value of 0.042 (OR = 1.406; 95%CI = 1.011-1.956), rs651821 with a p value of 0.007 (OR = 0.760; 95%CI = 0.622-0.929) and rs662799 with a p value of 0.006 (OR = 0.755; 95%CI = 0.618-0.923). In the genetic model analysis, we found the minor allele "A" of rs693 was associated with an increased ischemic stroke risk in the additive model and dominant model. The minor allele "C" of rs651821 was associated with a decreased ischemic stroke risk in the additive model. The minor allele "G" of rs662799 was associated with a decreased ischemic stroke risk in the additive model. Additionally, strong linkage was found in 3 blocks constituted by rs1042034, rs676210, rs693, rs673548 in APOB; rs3791981, rs679899 in APOB; and rs651821, rs662799, rs17120035 in APOA5. Our data suggested that gene polymorphisms in the APO genes may exert influences ischemic stroke susceptibility in a Chinese Han population.

Entities:  

Keywords:  APO; Chinese Han population; case-control study; gene polymorphisms; ischemic stroke

Year:  2017        PMID: 28947988      PMCID: PMC5601156          DOI: 10.18632/oncotarget.15549

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


INTRODUCTION

In recent years, ischemic stroke is becoming the most seriously disabling illness in industrialized countries [1]. As the population growth and aging in the world, the incidence of ischemic stroke is increasing every year. We have to take action now to look for some novel targets for new therapeutic strategies [2]. Previous study have suggested that the ischemic stroke is a multifactorial disease which is influenced by many factors, such as age, gender, obesity, smoking status, history of hypertension, diabetes and abnormal lipid metabolism as well as gene variation [3, 4]. Recent studies have identified several predisposing genes that are associated with ischemic stroke risk, including HDAC9 [5], LTC4S, ALOX5 [6], APOA1, APOB [7]. The protein encoded by APOA1 is the major protein component of high density lipoprotein (HDL) in plasma. Defects in APOA1 are associated with HDL deficiencies, including Tangier disease and systemic non-neuropathic amyloidosis [8]. APOA1 is closely linked with APOA5, which is another apolipoprotein gene on chromosome 11. The apolipoprotein encoded by APOA5 regulates the plasma triglyceride levels. Previous study have found that APOA5 mutations are associated with hypertriglyceridemia and hyperlipoproteinemia type 5 [9]. The protein encoded by APOB is the main apolipoprotein of chylomicrons and low density lipoproteins (LDL). Mutations in APOB or its regulatory region cause hypobetalipoproteinemia, normotriglyceridemic hypobetalipoproteinemia and hypercholesterolemia [10]. Additionally, APO levels have a closely correlation with lipid levels in the human body, and APOB/APOA1 could be used for predicting of abnormal lipid metabolism related disease [7]. To date, several independent studies suggest that APOA1, APOA5 and APOB levels are risk factors for ischemic stroke risk in Western populations. However, little is known about the contribution of APOA1, APOA5 and APOB genes polymorphisms to ischemic stroke risk, especially in the Chinese Han population. We therefore performed a case-control study to investigate the associations between single nucleotide polymorphisms (SNPs) in APOA1, APOA5 and APOB, and the risk of ischemic stroke in Chinese Han population.

RESULTS

This study included 488 ischemic stroke cases (325 men, 163 women; mean age 63.96 ± 11.06 years) and 503 healthy controls (196 men, 308 women; mean age 50.36 ± 7.89 years). The clinical characteristics of cases and controls are shown in Table 1. Age (p < 0.001) and sex (p < 0.001) were significantly different between cases and healthy controls. Multivariate analyses were adjusted for age and sex.
Table 1

Basic characteristics of case and control subjects

VariablesCase (n= 488)Control (n=503)p value
No.%No.%
Sex
Male32566.619538.9p<0.001a
Female16333.430861.1
Age
Mean ± SD63.96 ± 11.0650.36 ± 7.89p <0.001b

values were calculated by two-sided chi-square tests;

values were calculated from Student t tests.

values were calculated by two-sided chi-square tests; values were calculated from Student t tests. To design the multiplexed SNPs MassEXTEND assay, we used Sequenom MassARRAY Assay Design 3.0 Software (PCR primers are shown in Table 2). The minor allele frequencies (MAFs) of the analyzed SNPs in the case and control groups are shown in Table 3. All SNPs were in Hardy-Weinberg equilibrium (HWE) in the controls (p > 0.05). We found three SNPs were significantly associated with ischemic stroke: rs693 with a p value of 0.042 (OR = 1.406; 95%CI = 1.011-1.956), rs651821 with a p value of 0.007 (OR = 0.760; 95%CI = 0.622-0.929) and rs662799 with a p value of 0.006 (OR = 0.755; 95%CI = 0.618-0.923).
Table 2

PCR primers used for this study

SNP_ID1st-PCR primer sequences2nd-PCR primer sequencesUEP sequences
rs1042034ACGTTGGATGATGAAGATTAAGGCATAGGACGTTGGATGATCCAAGATGAGATCAACACATGAGATCAACACAATCTTCA
rs1801702ACGTTGGATGTCCTTTCGAGTTAAGGAAACACGTTGGATGGGCTTTAAATACCTCTTGGGTGATAAATCTTTCAACAGTTCC
rs676210ACGTTGGATGATAGCTTGCCAAAAGTAGGACGTTGGATGTTTTCAAGTTCCTGACCTTCggtccAGTTCCTGACCTTCACATAC
rs693ACGTTGGATGGGTATCGTTGAAGTTCCTGCACGTTGGATGCACATGAAGGCCAAATTCCGaGCCAAATTCCGAGAGAC
rs673548ACGTTGGATGCTTTCAGTGCATTGTCCAGACGTTGGATGAAGAGCAATGAACATTAGGCGAACATTAGGCAAAAATACC
rs3791981ACGTTGGATGCTACCTAGCTACCTCAAATCACGTTGGATGGTTTTGAGAATGAAGAAACAAGAATGAAGAAACAATAGCTC
rs679899ACGTTGGATGTCCATGACAGTTGGAAGTTGACGTTGGATGATAACATGGTGTGTCAGCTCCTGAAAAAGTTAGTGAAAGAAG
rs512535ACGTTGGATGTTCCGGTGGGAAATGGGCAGACGTTGGATGCCTCATAGACATCTGGAACCaCATGCATCGTTTCCTTC
rs651821ACGTTGGATGCTCCCTCCACCTGTCTTCTACGTTGGATGAGACCCACCTGAAAGAAGAGCAGCCATGCTTGCCATTA
rs662799ACGTTGGATGAGCATTTGGGCTTGCTCTCCACGTTGGATGTCTGAGCCCCAGGAACTGGAcctGAACTGGAGCGAAAGT
rs17120035ACGTTGGATGTACACACGTTCACAAGCTCCACGTTGGATGCTGGTGCAATGATGGTAGTGGGATTGATTCAAGATGCATTTA
rs9804646ACGTTGGATGCTGGGTTCTGATTCTGGTTGACGTTGGATGGTTTGAGGAGATCAAGTGGCACGTTGGATGCTTTCAGTGCATTGTCCAG
rs5072ACGTTGGATGTGTGACCCTGCCTGGAGATACGTTGGATGCCGAGTCCTCACCTAATATCgaatATGGTCTGGATGGAGAAAC
rs632153ACGTTGGATGAGCTGTGCTCCTGGAGGCTGACGTTGGATGAGGGACATGAGCAACCCTTCAGCTGGAGAAGGCAAAG
Table 3

Allele frequencies in cases and controls and odds ratio estimates for ischemic stroke risk (adjusted for gender and age)

SNP IDChromosomePositionAlleleGeneRoleHWE pMAFOR(95%CI)p value
A/BCaseControl
rs1042034221225281T/CAPOBCoding exon0.12470.2970.2821.075(0.885-1.305)0.467
rs1801702221225485G/CAPOBCoding exon10.0270.0290.922(0.539-1.577)0.767
rs676210221231524G/AAPOBCoding exon0.15340.2950.2831.057(0.870-1.284)0.577
rs693221232195A/GAPOBCoding exon0.26390.0910.0671.406(1.011-1.956)0.042*
rs673548221237544G/AAPOBIntron (boundary)0.15260.2950.2841.056(0.869-1.283)0.581
rs3791981221245367G/AAPOBIntron0.12670.0460.0510.905(0.600-1.365)0.634
rs679899221250914G/AAPOBCoding exon0.87620.1840.1731.081(0.859-1.361)0.505
rs512535221267782T/CAPOBPromoter0.72020.2560.2491.041(0.850-1.275)0.696
rs65182111116662579C/TAPOA55′ UTR0.91390.2380.2910.760(0.622-0.929)0.007*
rs66279911116663707G/AAPOA5Promoter10.2380.2920.755(0.618-0.923)0.006*
rs1712003511116663851T/CAPOA5Promoter10.1000.1001.000(0.746-1.341)0.999
rs980464611116665079T/CAPOA5Promoter0.89330.2210.2111.064(0.859-1.318)0.567
rs507211116707583A/GAPOA1Intron0.54630.3330.3331.001(0.831-1.207)0.988
rs63215311116710239T/GAPOA1Promoter0.45230.0650.0651.001(0.700-1.433)0.995

SNP single nucleotide polymorphism, HWE Hardy-Weinberg equilibrium, MAF minor allele frequency, OR odds ratio, CI confidence interval.

*p ≤ 0.05 indicates statistical significance.

SNP single nucleotide polymorphism, HWE Hardy-Weinberg equilibrium, MAF minor allele frequency, OR odds ratio, CI confidence interval. *p ≤ 0.05 indicates statistical significance. We further assessed the association between each SNP and ischemic stroke risk in an unconditional logistic regression analysis, which was performed using three models: additive, dominant and recessive model (Table 4). The minor allele “A” of rs693 in APOB was associated with an increased ischemic stroke risk in the additive model (OR = 1.583; 95 % CI = 1.045 - 2.397; p = 0.030) and dominant model (OR = 1.610; 95 % CI = 1.024 - 2.530; p = 0.039) respectively. The minor allele “C” of rs651821 in APOA5 was associated with a decreased ischemic stroke risk in the additive model (OR = 0.773; 95 % CI = 0.597 - 0.999; p = 0.040). The minor allele “G” of rs662799 in APOA5 was associated with a decreased ischemic stroke risk in the additive model (OR = 0. 768; 95 % CI = 0.593 - 0.993; p = 0.044).
Table 4

Association between APO SNPs and ischemic stroke risk in multiple inheritance models (adjusted for gender and age)

SNP IDMinor AlleleAdditive modelDominant modelRecessive model
OR (95% CI)p valueOR (95% CI)p valueOR (95% CI)p value
rs1042034T1.143 (0.895-1.461)0.2841.218 (0.881-1.684)0.2331.111 (0.642-1.923)0.707
rs1801702G0.962 (0.483-1.917)0.9120.940 (0.463-1.909)0.864-0.999
rs676210G1.119 (0.875-1.431)0.3721.196 (0.865-1.653)0.2801.046 (0.600-1.823)0.874
rs693A1.583 (1.045-2.397)0.030*1.610 (1.024-2.530)0.039*2.685 (0.484-14.890)0.258
rs673548G1.109 (0.867-1.419)0.4091.180 (0.853-1.632)0.3191.044 (0.599-1.818)0.880
rs3791981G0.770 (0.457-1.297)0.3260.792 (0.450-1.393)0.4190.276 (0.022-3.536)0.323
rs679899G1.019 (0.757-1.372)0.9011.059 (0.751-1.492)0.7450.795 (0.316-2.003)0.627
rs512535T0.971 (0.748-1.262)0.8280.965 (0.751-1.492)0.8290.965 (0.502-1.857)0.915
rs651821C0.773 (0.597-0.999)0.040*0.743 (0.536-1.028)0.0730.659 (0.352-1.231)0.190
rs662799G0.768 (0.593-0.993)0.044*0.735 (0.531-1.017)0.0630.660 (0.353-1.233)0.193
rs17120035T0.999 (0.688-1.453)0.9980.971 (0.644-1.462)0.8871.472 (0.323-6.588)0.613
rs9804646T1.071 (0.812-1.413)0.6261.056 (0.758-1.472)0.7461.261 (0.589-2.700)0.551
rs5072A0.915 (0.716-1.170)0.4800.869 (0.627-1.204)0.3980.961 (0.567-1.627)0.882
rs632153T1.028 (0.641-1.651)0.9081.050 (0.644-1.711)0.8440.355 (0.008-16.740)0.599

SNP single nucleotide polymorphism, OR odds ratio, CI confidence interval.

*p ≤ 0.05 indicates statistical significance.

SNP single nucleotide polymorphism, OR odds ratio, CI confidence interval. *p ≤ 0.05 indicates statistical significance. We further characterized the SNPs in APOs using linkage disequilibrium (LD) and haplotype analyses. Figure 1 showed the two blocks in APOB constructed by rs1042034, rs676210, rs693, rs673548 and rs3791981, rs679899 in chromosome 2 with D' = 1. Figure 2 showed the block in APOA5 constructed by rs651821, rs662799 and rs17120035 in chromosome 11 with D' = 1. The association analysis between the three blocks and ischemic stroke risk was shown in Table 5. The haplotype “TGAG” in APOB constructed by rs1042034, rs676210, rs693 and rs673548 in chromosome 2 was associated with an increased ischemic stroke risk (OR = 1.583; 95 % CI = 1.045 - 2.397; p = 0.031). The haplotype “CGC” in APOA5 constructed by rs651821, rs662799 and rs17120035 in chromosome 11 was associated with a decreased ischemic stroke risk (OR = 0.770; 95 % CI = 0.595 - 0.997; p = 0.047).
Figure 1

D' linkage map for the 8 SNPs in APOB

Figure 2

D' linkage map for the 6 SNPs in APOA1 and APOA5

A standard color scheme was used to display linkage disequilibrium (LD), with bright red corresponding to strong LD (LOD = 2, D' = 1), white corresponding to no LD (LOD < 2, D' < 1), and pink/red (LOD = 2, D' < 1) and blue (LOD < 2, D' = 1) corresponding to intermediate LD.

Table 5

Haplotype frequencies of APO genes and the association with ischemic stroke risk in cases and control (adjusted for gender and age)

ChromosomeGeneSNPsHaplotypeFrequencyFrequencyOR95% CIp value
CaseControl
chr2APOBrs1042034|rs676210|rs693|rs673548TGAG0.0910.0671.5831.0452.3970.030*
TGGG0.2030.2160.9400.7141.2380.659
CAGA0.7010.7170.8730.6831.1150.276
chr2APOBrs3791981|rs679899GG0.0460.0500.7740.4591.3060.338
AG0.1380.1231.1390.8151.5920.447
AA0.8160.8260.9840.7311.3240.913
chr11APOA5rs651821|rs662799|rs17120035TAT0.1000.1001.0000.6881.4530.998
CGC0.2380.2910.7700.5950.9970.047*
TAC0.6620.6071.2450.9851.5730.067

SNP single nucleotide polymorphism, OR odds ratio, CI confidence interval.

*p ≤ 0.05 indicates statistical significance.

D' linkage map for the 6 SNPs in APOA1 and APOA5

A standard color scheme was used to display linkage disequilibrium (LD), with bright red corresponding to strong LD (LOD = 2, D' = 1), white corresponding to no LD (LOD < 2, D' < 1), and pink/red (LOD = 2, D' < 1) and blue (LOD < 2, D' = 1) corresponding to intermediate LD. SNP single nucleotide polymorphism, OR odds ratio, CI confidence interval. *p ≤ 0.05 indicates statistical significance.

DISCUSSION

In the current study, we evaluated the association between fourteen SNPs in three APO genes and ischemic stroke risk in the Chinese Han population. We found the minor allele “A” of rs693 was associated with an increased ischemic stroke risk. The minor allele “C” of rs651821 and “G” of rs662799 have a protective role for ischemic stroke. The SNP rs693 at chromosome 2p24.1 was located in the exon region of APOB gene. The minor allele “A” of rs693 in codon 3611 resulted in amino acid substitution of glutamine to arginine, which could further changed the LDL-receptor binding affinity [11]. Previous studies demonstrated rs693 have a closely correlation with cholesterol and LDL-cholesterol levels [12-15]. Our study demonstrated rs693 was associated with ischemic stroke risk in a Chinese Han population, the detailed mechanism of how the SNP affected the progressing of ischemic stroke deserved further investigation. The SNP rs651821 and rs662799 at chromosome 11q23.3 was located in the 5′ UTR and promoter region of APOA5 gene respectively. As demonstrated by previous studies, the elevated triglyceride level may be an independent risk factor for ischemic stroke [16]. Human and animal data consistently show that the newly identified APOA5 gene may play an important role in the development of ischemic stroke and triglyceride metabolism [17, 18]. APOA5-1131T/C (rs662799), as one polymorphism site of APOA5, has been widely studied in ischemic stroke susceptibility. However, inconclusive results have been obtained. Some studies supported the conclusion that risk for ischemic stroke was associated with the polymorphism, whereas other studies drew converse conclusions [17-22]. Our study supported rs662799 was associated with ischemic stroke risk in a Chinese Han population, further meta-analysis will be need to confirm the results. The haplotype analysis suggested that the combination of certain SNPs could increase or decrease the risk of ischemic stroke since the change of a certain SNP may affect the change of another SNP thus generating a joint effect in the progressing of ischemic stroke. The detailed mechanism of this phenomenon deserved further investigation. Our study had several intrinsic limitations. For example, ischemic stroke is a very complicated process, and environment factors such as eating and exercise habits are important risk factors for ischemic stroke. Because our study had a relatively small sample size, and it did not incorporate data regarding eating and exercise habits, we could not explore the interactions between genetic polymorphisms and environmental factors in ischemic stroke. Therefore, the relationship between APOs polymorphisms and environment factors in ischemic stroke must be evaluated in future studies. In sum, our present study provided evidence that three SNPs rs693, rs651821 and rs662799 were associated with ischemic stroke risk in a Chinese Han population, which could be used in clinical diagnosis of ischemic stroke. Further investigations are deserved to discover more susceptible loci to other cardiovascular diseases, and to clarify the molecular mechanism of ischemic stroke.

MATERIALS AND METHODS

Study subjects

All the participants in this study were Han Chinese lived in Hainan Province. A total of 488 patients who diagnosed with ischemic stroke were recruited from the Haikou People's Hospital between January 2013 and February 2016. They were all newly diagnosed to be ischemic stroke patients according to the International Classification of Disease (9th revision, codes 430 to 438) on the basis of history, clinical symptoms, physical examination, and cranial computed tomography or magnetic resonance imaging. Patients with hemorrhagic stroke, subarachnoid hemorrhage, transient ischemic attack, traumatic brain injuries, infectious diseases, and tumors were excluded in this study. We also recruited 503 controls at the Haikou People's hospital. Controls were healthy, unrelated individuals selected randomly from the medical examination center of the hospital. All participants were informed of the procedures and purpose of the study, and each participant provided signed informed consent forms. The use of human samples in this study was approved by the Ethics Committees of the local participating hospitals and was in accordance with Department of Health and Human Services (DHHS) regulations for protection of human research subjects.

Polymorphisms selection and genotyping assays

Candidate SNPs in the APO genes were selected from previously published polymorphisms associated with stroke [23, 24]. Validated tSNPs were selected with a MAF > 5% in the HapMap CHB population. A total of 14 SNPs in the APO genes including 2 SNPs in APOA1, 4 SNPs in APOA5 and 8 SNPs in APOB were selected for further genotyping. Genomic DNA was extracted from peripheral blood leukocytes using the GoldMag® nanoparticles method (GoldMag Ltd. Xi'an, China) according to the manufacturer's instructions and DNA concentration was measured using the NanoDrop 2000 (Thermo Scientific, Waltham, Massachusetts, USA). We used Sequenom MassARRAY Assay Design 3.0 Software to design Multiplexed SNP MassEXTEND assays [25]. SNP genotyping was performed using the Sequenom MassARRAY RS1000 with a standard protocol recommended by the manufacturer [25]. Data management and analyses were performed using the Sequenom Typer 4.0 software as previously described [25, 26].

Statistical analysis

Statistical analyses were performed using Microsoft Excel (Redmond, WA, USA) and SPSS 16.0 statistical package (SPSS, Chicago, IL, USA). All p values in this study were two-sided, and p ≤ 0.05 was considered as the statistical significance threshold [27]. An exact test was used to assess the departure of each SNP frequency from Hardy-Weinberg equilibrium (HWE) in controls. We compared allele frequencies between cases and controls using a χ2 test. p values were calculated using unconditional logistic regression analysis with adjustment for age and gender [28, 29]. The three genetic models (dominant, recessive and additive) were applied by PLINK software (http://www.cog-genomics.org/plink2/) to assess the association of single SNPs with the risk of ischemic stroke. The odds are a way of representing probability, especially familiar for betting. The confidence intervals are standard errors for the log odds ratio. The odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated by unconditional logistic regression analyses adjusted for age and sex [30]. We used the Haploview software package (version 4.2) to analyze the linkage disequilibrium (LD), haplotype construction, genetic association at polymorphism loci and a D' value greater than 0.8 indicated that the related SNPs formed one block [31]. Marker information, including name and location is loaded separately. The program filters out markers which fall below 5% for subsequent steps. Haplotypes with frequencies > 1% were selected for analysis of ischemic stroke risk.
  30 in total

Review 1.  Molecular basis of ethnic differences in drug disposition and response.

Authors:  H G Xie; R B Kim; A J Wood; C M Stein
Journal:  Annu Rev Pharmacol Toxicol       Date:  2001       Impact factor: 13.820

Review 2.  Pharmacogenomics.

Authors:  Olivier Tribut; Yvon Lessard; Jean-Michael Reymann; Hervé Allain; Danièle Bentué-Ferrer
Journal:  Med Sci Monit       Date:  2002-07

3.  SNP genotyping using Sequenom MassARRAY 7K platform.

Authors:  Stacey Gabriel; Liuda Ziaugra
Journal:  Curr Protoc Hum Genet       Date:  2004-09

4.  Infarcts of undetermined cause: the NINCDS Stroke Data Bank.

Authors:  R L Sacco; J H Ellenberg; J P Mohr; T K Tatemichi; D B Hier; T R Price; P A Wolf
Journal:  Ann Neurol       Date:  1989-04       Impact factor: 10.422

5.  Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study.

Authors:  Martin J O'Donnell; Denis Xavier; Lisheng Liu; Hongye Zhang; Siu Lim Chin; Purnima Rao-Melacini; Sumathy Rangarajan; Shofiqul Islam; Prem Pais; Matthew J McQueen; Charles Mondo; Albertino Damasceno; Patricio Lopez-Jaramillo; Graeme J Hankey; Antonio L Dans; Khalid Yusoff; Thomas Truelsen; Hans-Christoph Diener; Ralph L Sacco; Danuta Ryglewicz; Anna Czlonkowska; Christian Weimar; Xingyu Wang; Salim Yusuf
Journal:  Lancet       Date:  2010-06-17       Impact factor: 79.321

6.  Apolipoprotein A5 gene promoter region T-1131C polymorphism associates with elevated circulating triglyceride levels and confers susceptibility for development of ischemic stroke.

Authors:  Viktória Havasi; Zoltán Szolnoki; Gábor Talián; Judit Bene; Katalin Komlósi; Anita Maász; Ferenc Somogyvári; András Kondacs; Mihály Szabó; Lajos Fodor; Anita Bodor; Béla Melegh
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

7.  Apolipoprotein A5 gene IVS3+G476A allelic variant confers susceptibility for development of ischemic stroke.

Authors:  Anita Maasz; Peter Kisfali; Luca Jaromi; Katalin Horvatovich; Zoltan Szolnoki; Veronika Csongei; Eniko Safrany; Csilla Sipeky; Ferenc Hadarits; Bela Melegh
Journal:  Circ J       Date:  2008-07       Impact factor: 2.993

8.  Association of ALOX5, LTA4H and LTC4S gene polymorphisms with ischemic stroke risk in a cohort of Chinese in east China.

Authors:  Gan-Nan Wang; Jin-Song Zhang; Wei-Juan Cao; Hao Sun; Jing Zhang; Yao Wang; Hang Xiao
Journal:  World J Emerg Med       Date:  2013

9.  Higher levels of serum triglyceride and dietary carbohydrate intake are associated with smaller LDL particle size in healthy Korean women.

Authors:  Oh Yoen Kim; Hye Kyung Chung; Min-Jeong Shin
Journal:  Nutr Res Pract       Date:  2012-04-30       Impact factor: 1.926

10.  Effect of the 3'APOB-VNTR polymorphism on the lipid profiles in the Guangxi Hei Yi Zhuang and Han populations.

Authors:  Yin Ruixing; Chen Guangqin; Wang Yong; Lin Weixiong; Yang Dezhai; Pan Shangling
Journal:  BMC Med Genet       Date:  2007-07-17       Impact factor: 2.103

View more
  3 in total

1.  Analysis of the APOB Gene and Apolipoprotein B Serum Levels in a Mexican Population with Acute Coronary Syndrome: Association with the Single Nucleotide Variants rs1469513, rs673548, rs676210, and rs1042034.

Authors:  Maricela Aceves-Ramírez; Yeminia Valle; Fidel Casillas-Muñoz; Diana Emilia Martínez-Fernández; Brenda Parra-Reyna; Víctor Arturo López-Moreno; Héctor Enrique Flores-Salinas; Emmanuel Valdés-Alvarado; José Francisco Muñoz-Valle; Texali García-Garduño; Jorge Ramón Padilla-Gutiérrez
Journal:  Genet Res (Camb)       Date:  2022-03-31       Impact factor: 1.588

2.  Plasma proteomics reveals coagulation, inflammation, and metabolic shifts in H-type hypertension patients with and without acute ischemic stroke.

Authors:  Feng Zhou; Lv Zhou; Tie Guo; Nianzhen Wang; Haizhen Hao; Yanhui Zhou; Dan Yu
Journal:  Oncotarget       Date:  2017-11-01

3.  Association between MicroRNA-4669 Polymorphism and Ischemic Stroke in a Korean Population.

Authors:  Seoung-Jin Hong; Su Kang Kim; Dong Hwan Yun; Jinmann Chon; Hae Jeong Park
Journal:  Dis Markers       Date:  2019-11-05       Impact factor: 3.434

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.